Cellect Biotechnology logo

APOP - Cellect Biotechnology News Story

$2.74 0.0  0.4%

Last Trade - 15/01/21

Sector
Healthcare
Size
Micro Cap
Market Cap £4.60m
Enterprise Value £84.6k
Revenue £n/a
Position in Universe 6086th / 6547

BUZZ-Cellect: Rises on deal to study its stem cell tech for COVID-19 patients

Mon 18th May, 2020 2:17pm
** Shares of Israel-based stem cell therapy co  APOP.O  rise
7.40% $3.34 premarket
    ** Co signs development agreement with international
consortium to study if stem cells treated with its technology
platform ApoGraft is effective in reducing lung-related issues
caused by COVID-19  urn:newsml:reuters.com:*:nPn9w1KgGa
    ** ApoGraft's technology is shown to prevent graft versus
host disease (GvHD) - when transplanted cells attack cells of
the patient receiving the transplant - in clinical trial
settings
    ** GvHD effects similar to cytokine storm, an overreaction
of the body's immune system, seen in COVID-19 patients and co
says approached by consortium use clinical data and regulatory
approvals of ApoGraft to speed up development of a cytokine
storm therapy for COVID-19 patients 
    ** Agreement allows co to receive royalties once products
are commercialized - APOP
    ** Up to last close, APOP stock down 40% YTD
    
       
    

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.